Development of antigen capture ELISA for the quantification of EIAV p26 protein
- 458 Downloads
An antigen capture enzyme-linked immunosorbent assay (AC-ELISA) was established based on two monoclonal antibodies (mAbs) for the quantification of equine infectious anemia virus (EIAV). Two p26-specific monoclonal antibodies were developed in mice. The mAb 9H8 was coated in microtiter plates as the capture antibody; the other mAb, 1G11, was coupled to horseradish peroxidase (HRP) and used as the detection antibody. The limit of detection for the EIAV p26 protein was 0.98 ng/ml, and the linearity range was 3.9–62.5 ng/ml. The sensitivity of p26 AC-ELISA for the detection of the virus (EIAV infectious clone, FDDVcmv3–8) was the same as that for the purified p26 protein. No cross-reaction with other equine viruses was observed by this method. The intra- and inter-assay coefficients of variation were below 8.3 and 10.3 % for testing p26 and FDDVcmv3–8, respectively. The AC-ELISA was also compared to Western blotting (WB) and reverse transcriptase (RT) assays, validating the sensitivity, accuracy, and reliability of this method. Both the AC-ELISA and RT assay showed good agreement, with a correlation coefficient of R 2 = 0.9946. Sample analysis showed that this AC-ELISA is a useful tool for quantifying EIAV p26 in cell lysates and culture medium.
KeywordsAC-ELISA EIAV p26 Capsid protein Quantitation of viral load
This study was supported by grants from the National Natural Science Foundation of China (31222054 to Xiaojun Wang and 31300713 to Zhe Hu) and grants from the State Key Laboratory of Veterinary Biotechnology (SKLVBP201426 to Zhe Hu).
Conflict of interest
The authors have no conflicts of interest to declare.
- Craigo JK, Montelaro R (2008) Equine infectious anemia virus (Retroviridae). Encyclopedia of virology, vol 3. Elsevier, Oxford, pp 167–174Google Scholar
- Mascola JR, D’Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC (2005) Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79(16):10103–10107PubMedCrossRefPubMedCentralGoogle Scholar
- Montelaro RC, Ball J, Rushlow KE (1993) In: Levy JA (ed) The Retroviridae, vol 2. Plenum, New York, pp 257–360Google Scholar
- Rongxian SZW (1983) Development and use of an equine infectious anemia donkey leukocyte attenuated vaccine. In: Tashijan R (ed) Equine infectious anemia virus: a national review of policies, programs, and future objectives. American Quarter Horse Association, Amarillo, TX, pp 135–148Google Scholar